Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Most Cited Paper
in Cancer-related Molecular Pathways
18 Months Post-Publication
Class of 2026
“Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
ribociclib · CDK4/6 inhibitor · endocrine therapy · combination chemotherapy · hormone receptor-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · premenopausal women · clinically aggressive disease · letrozole · anastrozole · goserelin · docetaxel plus capecitabine · paclitaxel plus gemcitabine · capecitabine plus vinorelbine · visceral disease · visceral crisis · progression-free survival · Overall response rate · time to response
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459